Patient characteristics and treatment patterns for patients with advanced/metastatic gastric cancer (including gastroesophageal junction cancer) or esophageal cancer in Puerto Rico.

Abstract

537 Background: The aim of the study was to describe patient characteristics and treatment patterns across lines of therapy in patients with advanced/metastatic Gastric Cancer -including gastroesophageal junction cancer- (GC/GEJC) or Esophageal Cancer (EC) in Puerto Rico (PR). Methods: This was a descriptive retrospective observational cohort study using Flatiron Health Oncology EHR database. Eligible PR adults diagnosed with advanced/metastatic GC/GEJC/EC were required to have ≥ 1 months of medical data from January 1, 2011, through April 30, 2022 (index period). The index date was defined as the date of advanced/metastatic GC/GEJC/EC diagnosis. Patients who were enrolled in clinical trials any time during the study period and with other primary cancers prior to the index date were excluded. The demographics, clinical characteristics, treatment regimen received and duration of therapy (DoT) across lines of therapy were assessed for patients categorized into GC/GEJC and EC subgroups. Results: A total of 206 patients were included in the GC/GEJC (n= 115) and EC (n=91) subgroups. The mean follow-up time from index date was 15.6 and 15.7 months (GC/GEJC and EC, p=0.977). Patients in both subgroups had a similar mean age of 66.8 and 68.3 (GC/GEJC and EC; p=0.328). Among patients who had a ECOG evaluation the 0-1 status was similar 88.5% and 87.1% (GC/GEJC and EC; p=0.297). Patients (GC/GEJC vs EC for all) differed in the percentage of males (59.1% vs 81.3%, p=0.001), stage IV at initial diagnosis (57.4% vs 37.4%, p=0.003) and smoking history (30.4% vs 52.7%, p=0.005). Most patients received at least one line of therapy 79.1% and 84.6% (GC/GEJC and EC, p=0.313). 89.9% of patients in first line (1L) therapy received chemotherapy either as monotherapy or in combination. 32.2% vs 39.6% (p=0.271) GC/GEJC and EC patients received second line (2L) therapy while 12.2% vs 13.2% (p=0.828) received third line (3L) and beyond. The median DoT in 1L was 3.1 and 2.3 months, for 2L was 2.1 and 3.6 months; and for 3L or more, 1.7 and 3.2 months for GC/GEJC and EC, respectively. Conclusions: Most patients in PR with advanced/metastatic GC/GEJC or EC received first-line treatment while only a third of patients received second line. In all lines of therapy, the duration of treatment for both cohorts was short.Future studies with a larger sample are warranted.